Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992.
Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.
From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet
Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice.
Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.
Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.
Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.
Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.
Find out about our current vacancies at Berlin-Chemie directly on our career portal.
Within the Menarini Group, Berlin-Chemie is the regional headquarters for the CEE and CIS region and is responsible for more than 30 countries and their local subsidiaries.
As a reliable partner in the healthcare sector, we want to use our products and expertise to help solve the complex challenges in the healthcare sector in these regions. To this end, Berlin-Chemie has established strong partnerships at all levels in many countries. We support doctors and patients with high-quality medical products and technologies to improve the quality of life.
BERLIN-CHEMIE AG
Glienicker Weg 125
12489 Berlin, Deutschland
E-mail: info@berlin-chemie.de
Phone: +49 (0)30 6707-0
Fax: +49 (0)30 6707-2120
Cardiovascular disorders are conditions affecting the heart and blood vessels that may have severe consequences if not treated consistently. There is a broad range of cardiovascular disorders from chronic conditions such as heart failure to acute events such as strokes. Cardiovascular disorders are responsible for 40 percent of all deaths in Germany,1 with coronary heart disease, heart attack and stroke accounting for the largest share.2 Coronary heart disease involves a narrowing of the coronary arteries, reducing the supply of blood to the heart muscle. If a coronary artery becomes completely blocked, this results in a heart attack. If an artery in the brain is blocked this causes stroke.
These conditions are often associated with risk factors such as high blood pressure, cholesterol, blood glucose as well as being overweight. Patient care has improved thanks to new testing and treatment procedures.
Sources:
1 RKI - Herz-Kreislauf-Erkrankungen (Last accessed: 18.01.2024)
2 Herz-Kreislauf-Erkrankungen (gesundheitsforschung-bmbf.de) (Last accessed: 18.01.2024)